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Summary Histologically it is nearly impossible to distinguish the dedifferentiated component of 
dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma of bone when the 
low-grade cartilaginous component is absent. Previous studies have revealed that isocitrate 
dehydrogenase 1 (IDH1) and IDH2 mutations are present in a significant number of cartilaginous 
tumors including the majority of conventional chondrosarcoma and dedifferentiated 
chondrosarcomas. These mutations have not been studied in undifferentiated pleomorphic 
sarcomas of bone. We sought to investigate whether an IDH1 or IDH2 mutation signature could 
be used as a clinically diagnostic marker for the distinction of dedifferentiated component of 
chondrosarcoma from undifferentiated pleomorphic sarcoma of bone. Sixty-eight bone tumor 
cases, including 31 conventional chondrosarcomas, 23 dedifferentiated chondrosarcomas, and 14 
undifferentiated pleomorphic sarcomas of bone, were collected for IDH1/2 mutation analysis 
either using the Qiagen IDH1/2 RGQ PCR Kit or using whole exome sequencing.  IDH1/2 
mutations were detected in 87% (20/23) of dedifferentiated chondrosarcomas and 30% (6/20) of 
conventional chondrosarcomas. No mutations were detected in the IDH1/2 codon 132 or codon 
172 among 14 UPS of bone. Identification of IDH1 or IDH2 mutations supports the diagnosis of 
dedifferentiated chondrosarcoma rather than undifferentiated pleomorphic sarcoma of bone 
while also providing some insight into the pathogenesis of these two lesions.  
Key Words: IDH1, IDH2, dedifferentiated chondrosarcoma, undifferentiated pleomorphic 
sarcoma (UPS) of bone  
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1. Introduction 
Chondrosarcoma, a malignant cartilaginous tumor, is the second most common primary 
malignancy of bone after osteosarcoma, often arising from the pelvis, femur, or humerus. 
Tumors are classified as conventional chondrosarcoma when the histology resembles non-
neoplastic cartilage, as opposed to dedifferentiated chondrosarcoma containing areas of high 
grade sarcoma. The most common morphological pattern of the dedifferentiated component is 
undifferentiated pleomorphic sarcoma (UPS), so-called malignant fibrous histiocytoma (MFH). 
Diagnosis of dedifferentiated chondrosarcoma relies on identifying both the well-differentiated 
cartilaginous and dedifferentiated components (1). UPS of bone is commonly located in the 
lower extremities, particularly the femur followed by tibia and pelvis. Morphologically, tumors 
are composed of atypical spindled and pleomorphic cells which may be arranged in a storiform, 
fascicular or haphazard pattern with marked nuclear pleomorphism, mitoses, and necrosis (2, 3). 
Importantly, these tumors lack chondroid and osteoid matrix deposition.   
 
Although dedifferentiated chondrosarcoma and UPS of bone may share clinical presentations, 
including arising in similar anatomical locations, dedifferentiated chondrosarcoma is extremely 
aggressive with a dismal prognosis.  Most patients with dedifferentiated chondrosarcoma die 
within 2 years of initial presentation. The 5-year survival rate is 19% based on a large study of 
52 cases but ranges from 7.1 to 24% in studies throughout the literature (4, 5). With the lack of 
convincing evidence of the benefit of chemotherapy, complete surgical excision is the initial 
recommended treatment. UPS of bone is also aggressive. However, neoadjuvant or adjuvant 
chemotherapy is beneficial with the improved 5-year survival rate up to 59% (median survival 
time 63 months) (3, 6). In fact, neoadjuvant chemotherapy using an osteosarcoma treatment 
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protocol is gradually becoming the standard of care particularly for high grade resectable UPS of 
bone (3). Therefore, differentiating these two entities is of paramount importance.  However, as 
there is significant morphologic overlap between UPS of bone and the dedifferentiated 
component of dedifferentiated chondrosarcoma, distinction often relies on the presence or 
absence of a low-grade cartilaginous component which may not be present with biopsy or limited 
sampling. To date, there are no reliable ancillary tests, such as immunohistochemistry, 
cytogenetics, or molecular studies, to improve diagnostic specificity.  
 
Point mutations in the isocitrate dehydrogenase 1 (IDH1) or IDH2 gene were originally detected 
in gliomas, secondary glioblastomas (7), and later identified in a variety of malignancies 
including some de novo acute myeloid leukemias (8, 9), myelodysplastic disorders (10), 
cholangiocarcinoma (11), thyroid carcinoma (12), prostate carcinoma, B cell lymphoma, and 
colorectal carcinomas (13).  Further studies have shown that the majority of chondrosarcomas, 
including dedifferentiated chondrosarcomas, harbor mutations in the metabolic enzyme IDH1 or 
IDH2 gene whereas osteosarcomas including chondroblastic, fibroblastic, osteoblastic subtypes, 
etc, lack these genetic abnormalities (14-16).  IDH is an important homodimeric enzyme in the 
citric acid cycle (the Krebs cycle) and normally catalyzes the decarboxylation of isocitrate (ICT) 
to α–ketoglutarate (α-KG).  IDH1 and IDH2 employ NADP+ as a cofactor and are located in the 
cytoplasm (IDH1), peroxisomes (IDH1), and mitochondria (IDH2) (17). Mutations almost 
always affect a single amino acid residue at arginine-132 in IDH1 or ariginine-172 in IDH2. The 
majority of mutations occur in IDH1 (14, 15). All reported IDH1 and IDH2 mutations are 
heterozygous, with cancer cells retaining one wild-type copy of the relevant IDH1 or IDH2 
allele. These mutations lead to a reduced capacity to convert ICT to α-KG and a gain of function 
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to convert α-KG to delta-2-hydroxyglutarate (D-2-HG), an oncometabolite (18). Typically, 
mutations in IDH1 or IDH2 are mutually exclusive (18). Biochemical analysis revealed a >100-
fold increase in D-2-hydroxygluturate in human glioma samples with IDH1 mutations while D-
2-hydroxygluturate is present at very low levels in normal tissue (19). The pathogenesis by D-2-
hydroxygluturate has been under extensive study (17, 19-21). 
 
The fact that IDH1/2 mutations are present in dedifferentiated chondrosarcoma and have not 
been studied in UPS of bone prompted us to evaluate whether an IDH1 and IDH2 mutation 
signature could be used as a molecular diagnostic marker to distinguish these two lesions, as well 
as give insight into the pathogenesis of these two lesions and provide useful information for 
clinical management.  
 
2. MATERIALS AND METHODS 
2.1 Ethics Statement 
This study was approved by the Institutional Review Board of Indiana University, Mayo Clinic 
and University of Alabama at Birmingham. Resected specimens were submitted for routine 
histological diagnoses and the remaining tissues were used for research. There was no 
compromise of the patient’s privacy. 
2.2 Collection of Tumor Specimens 
After searching pathology information system databases, cases of conventional chondrosarcoma 
and dedifferentiated chondrosarcoma were collected from Indiana University, Mayo Clinic, and 
the University of Alabama at Birmingham. Samples of primary undifferentiated pleomorphic 
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sarcomas of bone were collected from Musculoskeletal Pathology Department at the Royal 
Orthopaedic Hospital, Birmingham, UK. A significant number of conventional chondrosarcoma 
tissues were decalcified due to the presence of bone fragments. For a subset of dedifferentiated 
chondrosarcomas, both the conventional cartilaginous and the dedifferentiated components were 
available for mutation analysis from the same lesion. For each case, one or two hematoxylin and 
eosin–stained slides with tumor cells were selected by one pathologist at each institution and the 
corresponding formalin-fixed, paraffin-embedded tissue blocks were retrieved. Ten unstained 
sections (10 μm in thickness per section) were cut from each tissue block and mounted on 
uncharged slides (one section per slide). Areas with lesional cells on the unstained sections (at 
least 6–7 sections) were circled by comparing with the corresponding hematoxylin and eosin–
stained (H&E) slides and removed for DNA extraction. Necrotic tissue and surrounding paraffin 
were avoided.  
 
2.3 DNA Extraction 
DNA extraction from formalin-fixed, paraffin-embedded tissue was performed using a QIAamp 
DNA FFPE Tissue Kit (QIAGEN Catalog #56404, Valencia, CA) and recommended protocol. A 
few drops of 70% ethanol were added on the slide to wet the tissue section. The lesional cells 
were transferred to a 2 ml tube labeled with the case number by scraping the tissue off the slide. 
Major steps for DNA extraction included removal of paraffin, lysis of tissue, reversal of formalin 
crosslinking, DNA binding to a silica-based membrane, removal of contaminants, and eluting the 
DNA from the silica-based membrane. For the final steps, 50 μl distilled DNAse/RNAse-free 
water was applied to the center of the membrane of the QIAamp MinElute column for each 
specimen for 1 min at room temperature (15–25 °C). The specimen was centrifuged at full speed 
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(20,000×g; 15,000 rpm) for 1 min. The QIAamp MinElute column was discarded and the 
microcentrifuge tube containing eluted DNA was labeled with the appropriate specimen 
information. The DNA concentration was determined by measuring the optical density of the 
sample at 260 nm and diluted to a concentration of 5 ng/μl in 1×TE buffer at pH 8.0.  
2.4 Mutation Analysis by PCR 
PCR reaction mixes were prepared according to the number of samples being processed and the 
Rotor-Gene Q instrument was programmed with the thermal cycling program as mentioned in 
the IDH1/2 RGQ PCR Kit (QIAGEN Catalog #873001, Valencia, CA), This PCR kit detects 
multiple mutations in codon 132 of the IDH1 gene and codon 172 of the IDH2 gene, 
respectively. Reaction controls included the water control, the IDH1/2 wild-type control, and the 
mutated IDH1/2 positive control (Mut-PC). For each mutant assay, standards were set whereby 
the wild-type control had to be detected as mutation-negative and the Mut-PC had to be detected 
as mutation-positive. The entire experiment was invalid if both conditions were not met. For 
each specimen, ΔCT values were calculated for IDH1 Mut R132, IDH2 Mut R172, IDH1 Mut 
R100, IDH1 Mut R132H, IDH1 Mut R132C, and IDH2 Mut R172K. Samples were classified as 
mutation-positive (IDH1 Mut R132, IDH2 Mut R172, and IDH1 Mut R100) if the ΔCT value 
was less than or equal to the ΔCT cutoff value of the respective mutation detection assay. The 
sample specific mutation was identified (IDH1 Mut R132H, IDH1 Mut R132C, and IDH2 Mut 
R172K) if the ΔCT value was less than or equal to the ΔCT cutoff value of the respective 
mutation identification assay. Using the IDH1/2 RGQ PCR Kit, multiple mutations including 
R132H, R132C and four other R132 mutations in the codon 132 of IDH1, R172K and four other 
R172 mutations in the codon 172 of IDH2, and one R100 mutation in the codon of IDH1 could 
be detected. The other four IDH1 R132 mutations, R132S, R132G, R132L, and R132V, could 
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not be further defined due to IDH1/2 RGQ PCR Kit limitations and were simply designated as 
IDH1 R132. The same was true for the other four IDH2 R172 mutations which included R172M, 
R172W, R172S and R172G.  
2.5 Exome capture, DNA sequencing and IDH1/2 mutational hotspot analysis 
Genomic DNA of undifferentiated pleomorphic sarcoma (UPS) of the bone was extracted from 
thirteen fresh frozen tumors using a standard phenol–chloroform extraction protocol. For one 
FFPE sample (Table 3 case 12), DNA was extracted using the QIAamp DNA FFPE Tissue Kit 
(QIAGEN Catalog #56404), following the manufacturer’s protocol. Exome capture of sheared 
DNA fragments was performed using the Agilent SureSelect Human All Exon V5 kit following 
manufacturer's protocol (Agilent, Santa Clara, CA, USA). Paired end sequencing was performed 
using either Illumina 2x100bp (22) or NextSeq 2x150bp high output (23) protocols to achieve a 
50X average coverage. The reads were aligned to the human genome reference sequence 
GRCh37 using BWA 0.7.x (24) .  Using Integrative Genomics Viewer (IGV) 
(http://software.broadinstitute.org/software/igv/), the Binary Alignment Map (BAM) files for all 
samples were manually checked for variations in the mutational hotspot codons R132 and R172 
of IDH1/2 genes, respectively. 
2.6 Immunohistochemical Staining 
Immunohistochemical staining was performed according to a previously published protocol (25). 
Only two changes were made to the protocol: Antigen retrieval was performed using Tris-EDTA 
buffer, pH 9.0 in a PT module (Dako) for 15 minutes and a mouse anti-human IDH1 R132H 
monoclonal antibody (Catalog number DIA H09, Dianova, Hamburg, Germany) was used at 
1:60 dilution as a primary antibody to detect mutated IDH1 R132H enzyme. Human glioma was 
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used as a positive control. Cytoplasmic staining in the lesional cells of chondrosarcoma and 
dedifferentiated chondrosarcoma was considered a positive result. 
 
3. RESULTS  
3.1 Clinicopathologic Features 
A total of 68 cases were collected for IDH1/2 mutation analysis and included 31 conventional 
chondrosarcomas, 23 dedifferentiated chondrosarcomas, and 14 UPS of bone. Among the 31 
chondrosarcoma cases as shown in Table 1, the tumor size ranged from 1.5 cm in the cricoid to 
47.0 cm in the right pelvis (mean, 10.4 cm; median, 8.5 cm). Seventy-seven percent lesions arose 
from the femur (n=11), pelvis (n=5), sacrum (n=4), or rib (n=4). The tumor size of 
dedifferentiated chondrosarcoma (Table 2) ranged from 4.2 cm to 26.0 cm (mean, 11.6 cm; 
median, 9.9 cm). All but one were primary lesions; the exception being a metastatic lesion in the 
liver. The primary tumors mainly arose from the femur (n=8), humerus (n=6), and pelvis (n=5).  
The tumor size of UPS of bone (Table 3) ranged from 3.0 cm to 12.5 cm (mean, 8.3 cm; median, 
8.5 cm). The primary tumors mainly arose from the femur (n=9) and tibia (n=2).  
Cases of conventional chondrosarcoma showed hyaline cartilage neoplasms containing variable 
numbers of atypical chondrocytes with enlarged, hyperchromatic nuclei (Fig. 1A). Those 
classified as dedifferentiated chondrosarcoma were biphasic tumors with areas of low-grade 
chondrosarcoma juxtaposed to foci containing atypical spindle and epithelioid cells with marked 
nuclear atypia (Fig. 1B).  Typically, there was an abrupt transition between the cartilaginous and 
the non-chondrogenic sarcomatous component (Fig. 1C). UPS of bone revealed atypical spindle 
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and epithelioid cells with nuclear pleomorphism, hyperchromatism and readily-identifiable 
mitoses, lacking any specific line of differentiation by immunohistochemistry (Fig. 1D).  
3.2 Mutational Analysis  
Among the 31 cases of conventional chondrosarcoma, IDH1/2 mutation analysis was 
successfully performed in 20 (65%). Of the 20 successful samples, 6 (30%) harbored a somatic 
mutation in either IDH1 or IDH2 (Table 1). The majority of mutations were detected in the IDH1 
gene (n=4) and included R132H (1), R132C (2), and R132 (1) (not specified, see Materials and 
Methods). Two other R172 mutations were found in the IDH2 gene. Two of 4 grade 1 cases and 
4 of 14 grade 2 cases contained IDH1/2 mutations (Table 1).  Review of the pathology reports 
and H&E slides revealed that the 11 failed cases were previously decalcified with hydrochloric 
acid. Among 23 cases of dedifferentiated chondrosarcoma, 20 (87%) harbored a somatic 
mutation in either IDH1 or IDH2 (Table 2) in the dedifferentiated components. Specifically, they 
were 1 R132H, 5 R132C, and 5 R132 mutations in the IDH1 gene and 9 R172 mutations in the 
IDH2 gene. Both conventional cartilaginous and dedifferentiated regions were tested in 16 cases; 
however, analysis of both components was successful in only 3, revealing 2 IDH1 R132 and 1 
IDH2 R172 mutations.  The mutations were concordant for both components tested in all three 
cases. By analyzing Whole Exome Sequencing data of 14 cases of UPS of bone, mutations in 
IDH1/2 hotspots codon R132 and R172 were not detected (Table 3).  
 
3.3 Detection of IDH1 R132H Mutated Enzyme Expression Using Immunostaining 
One conventional chondrosarcoma (Table 1, case 1) and one dedifferentiated chondrosarcoma 
(Table 2, case 19) were found to contain single IDH1 R132H mutation. Therefore 
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immunostaining was performed to confirm the presence of the mutated IDH1 R132H protein 
expression in these two cases. Cytoplasmic staining was clearly demonstrated in the atypical 
chondrocytes of the conventional chondrosarcoma (Fig. 2B) and the dedifferentiated component 
the dedifferentiated chondrosarcoma (Fig. 2C).  
 
4. DISCUSSION 
Dedifferentiated chondrosarcoma is a highly aggressive biphasic mesenchymal tumor consisting 
of a well-differentiated cartilaginous component admixed with area of high-grade sarcoma.  With 
extensive sampling and careful correlation with radiologic findings, the diagnosis is often 
straightforward.  However, in the advent of core biopsy techniques, the conventional 
cartilaginous component can be easily missed. Specifically, if the biopsy only shows the high 
grade sarcomatous component, distinction from UPS of bone is nearly impossible with 
morphology alone.  As treatment protocols and prognosis differ for these two entities, accurate 
diagnosis is critical.  
 
Our results show that the presence of an IDH1 or IDH2 mutation strongly supports the diagnosis 
of dedifferentiated chondrosarcoma rather than UPS of bone. While an IDH1/2 mutation was 
identified in the dedifferentiated component of 87% (20 of 23 cases) of our dedifferentiated 
chondrosarcomas, no UPS of bone (0 of 14 cases) harbored a detectable aberration in these 
genes. Therefore, IDH1 and IDH2 mutational analysis seems to be a robust strategy to be used in 
distinguishing these two lesions. Interestingly, the incidence of IDH1/2 mutations in 
dedifferentiated chondrosarcoma in our series is slightly higher than what has previously 
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reported in the literature.  Amary and colleagues identified IDH1/2 mutations in 13 of 23 cases 
(56.5%) of dedifferentiated chondrosarcoma, while Meijer and coworkers found that 50% of 
dedifferentiated harbored IDH1/2 aberrations (14, 16). We also showed concordance of mutation 
status in both well-differentiated and dedifferentiated components in three cases in which both 
regions we successfully analyzed. This is consistent with the previous report which demonstrated 
the same mutation detected in both components (grade I and dedifferentiated) in four cases (14). 
While the concept of dedifferentiation has long been recognized, these findings provide further 
evidence to support shared pathogenesis for both components.  Furthermore, the absence of 
IDH1/2 mutations in UPS of bone yields insight into the biological difference between 
dedifferentiated chondrosarcoma and undifferentiated pleomorphic sarcoma of bone.  
 
Among a total of 11 cases of dedifferentiated chondrosarcoma with IDH1 mutations in this 
study, 1 case harbored an IDH1 R132H mutation, which was also confirmed by immunostaining 
using monoclonal antibody. Although the IDH1 R132H mutation occurs in approximately 70% 
of WHO grade II and III gliomas (7), it was detected in only 17% of the IDH 1/2 mutations 
present in cartilaginous tumors in one study (14) and 0% (0/14 positive cases) in another study 
(15).  While the IDH1 R132H monoclonal antibody appears to be a reliable surrogate for 
mutation status, the low rate of its prevalence in dedifferentiated chondrosarcoma limits its 
usefulness in this setting.  
 
In recent years there has been a strong and growing interest in performing molecular analysis of 
tumors in the era of precision medicine.  Even if IDH1/2 mutation status is not required for 
diagnosis, unique IDH1/2 signatures detected in dedifferentiated chondrosarcoma may lead to a 
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new approach for effective targeted therapy which may result in better survival rates and 
prognosis. Recent in vitro study revealed that high doses of IDH1 inhibitor AGI-5198 inhibited 
colony formation and migration, interrupted cell cycling, and induced apoptosis using 
chondrosarcoma cell lines, which revealed anti-tumor activity of the IDH1 inhibitor (17).  More 
in vitro and in vivo studies need to be performed to explore the possibility of finding specific and 
effective IDH1/2 mutation inhibitors available for targeted therapy of dedifferentiated 
chondrosarcoma.  
 
One potential drawback of performing mutational analysis on bone tumors is that the 
decalcification procedure involves hydrochloric acid which is known to cause DNA damage 
through chemical hydrolysis which has been previously discussed by Kerr and colleagues in their  
analysis of IDH1/2 mutations in chondoblastic osteosarcoma (15)  Consequently, tumor sections 
with significant bone matrix may be subjected to this process, often rendering them unsuitable 
for these studies. Eleven cases of conventional chondrosarcoma with unsuccessful mutation 
analysis were exposed to decalcification techniques (Table 1).  Fortunately, the dedifferentiated 
component of dedifferentiated chondrosarcoma, as well as UPS of bone, often lacks osteoid or 
bone matrix.  In our series, mutation analysis was successful in all 23 cases of dedifferentiated 
chondrosarcoma and 14 UPS of bone by selecting tissue sections not previously decalcified. 
Nonetheless, pathologists should be aware of the limitations of molecular analysis after 
decalcification procedures.  
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In summary, IDH1/2 mutation analysis is a useful tool for distinguishing dedifferentiated 
chondrosarcoma from undifferentiated pleomorphic sarcoma of bone to help ensure accurate 
diagnosis and appropriate treatment for these patients.  While there is no substitute for careful 
correlation with clinical and radiologic data in bone lesions, IDH1/2 mutation analysis is an 
ancillary technique which may be employed particularly for biopsy specimens when clinical 
information is lacking or radiologic findings are equivocal. Finally, this study gives insight into 
the difference in pathogenesis between dedifferentiated chondrosarcoma and UPS of bone. If 
effective IDH1/2 mutation inhibitors become available in the future, PCR mutation analysis on 
cases of dedifferentiated chondrosarcoma help guide treatment decisions.  
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Figure legends:  
FIGURE 1. Morphological features of malignant cartilaginous neoplasms and undifferentiated 
pleomorphic sarcoma of bone (objective lens x20, enlarged images in insets).  A, Conventional 
chondrosarcoma shows atypical chondrocytes with enlarged and hyperchromatic nuclei.  B, 
Dedifferentiated component of chondrosarcoma reveals atypical spindle and epithelioid cells 
with marked nuclear pleomorphism, hyperchromatism and prominent nucleoli. C, 
Dedifferentiated chondrosarcoma has an abrupt demarcation between the cartilaginous 
component and the dedifferentiated component. D, Undifferentiated pleomorphic sarcoma of 
bone shows atypical cells with nuclear pleomorphism, atypical mitosis and hyperchromatism 
without a specific line of differentiation.  
 
FIGURE 2. Immunostaining for IDH1 R132H mutated enzyme (objective lens x40). A, 
Standard positive control glioma with cytoplasmic staining. B, Cytoplasmic staining in 
conventional chondrosarcoma harboring IDH1 R132H mutation. C, Cytoplasmic staining of 
dedifferentiated component of chondrosarcoma with IDH1 R132H mutation. D, Dedifferentiated 
component of chondrosarcoma without IDH1 R132H mutation shows lack of immunoreactivity 
(negative control). 
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Figure 2 
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Table 1. Clinicopathologic Features and IDH1/2 Mutation Analysis of Conventional Chondrosarcoma 
Specimens 
Cases Age 
(y) 
Sex Site Sample 
Class 
Size 
(cm) 
Grade Decal Mutation 
status 
1 58 F Humerus Primary 5.0 G1 No IDH1 R132H 
2 75 M Femur Primary 9.0 G2 Yes failed 
3 48 M Calcaneus Primary 6.0 G1 Yes failed 
4 72 F Rib Primary 8.5 G1 No WT 
5 85 M Rib Primary 3.9 G1 No WT 
6 41 M Pelvis Primary 2.5 G1 Yes failed 
7 85 M Femur Primary 13.0 G1 Yes failed 
8 60 M Pelvis Primary 47.0 G2 No WT 
9 52 M Femur Primary 7.8 G2 No IDH1 R132C 
10 41 M Sacrum Primary 10.0 G2 No WT 
11 38 F Fibula Primary 3.5 G1 Yes failed 
12 87 F Femur Primary 7.0 G2 No WT 
13 77 F Pelvis Primary 7.0 G1 Yes failed 
14 43 M Femur Primary 6.0 G1 Yes failed 
15 38 M Rib Primary 13.3 G2 No WT 
16 27 M Fibula Primary 8.0 G1 Yes failed 
17 81 M Femur Primary 20.0 G1-2 Yes failed 
18 40 F Pelvis Primary 18.0 G1-2 No WT 
19 78 M Femur Primary 9.8 G1 No IDH1 R132C 
20 69 F Femur Primary 24.0 G2 Yes failed 
21 51 M Femur Primary 17.0 G2 No IDH2 R172 
22 32 M Scapula Primary 6.0 G1 Yes failed 
23 59 M Sacrum Recur  10.0 G2 No WT 
24 67 M Femur Primary 13.5 G2-3 No IDH1 R132  
25 57 M Sternum and 
rib 
Primary 11.2 G2 No WT 
26 59 M Sacrum Primary 4.0 G2 No WT 
27 57 M Sacrum Primary 5.0 G2 No WT 
28 31 M Femur Primary 10.0 G2 No IDH2 R172 
29 43 F Cricoid Primary 1.5 G2 No WT 
30 65 M Cricoid  Primary 3.8 G2 No WT 
31 47 M Pelvis Primary 10.0 G2 No WT 
Abbreviations: IDH, isocitrate dehydrogenase; ST, soft tissue; WT, wild type. 
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Table 2. Clinicopathologic Features and IDH1/2 Mutation Analysis of Dedifferentiated Chondrosarcoma 
Specimens 
Cases Age 
(y) 
Sex Site Size 
(cm) 
C-CHS 
grading 
C-CHS 
mutation 
Dediff 
CHS 
Decal 
Dediff CHS 
mutation 
1 63 F Femur 8.0 G2 Not tested No IDH1 R132 
2 60 M Humerus 10.0 G1 failed No IDH2 R172 
3 95 F Humerus 7.0 G1 Not tested No IDH2 R172 
4 63 M Femur 4.2 G3 Not tested No IDH2 R172 
5 63 F Femur 15.0 G2 failed No IDH1 R132C 
6 73 M Humerus 15.8 G3 failed No IDH2 R172 
7 72 F Humerus 9.5 G2 failed No WT 
8 58 F Pelvis 8.5 G2 failed No IDH1 R132C 
9 70 M Femur 6.0 G2 failed No IDH1 R132 
10 64 M Tibia 21.0 Unknown Not tested No IDH1 R132 
11 36 M Humerus 
/Scapula 
26.0 G3 failed No IDH1 R132C 
12 72 F Pelvis 5.5 G1 failed No IDH1 R132C 
13 43 M Coracoid 
Process 
12.0 G1 IDH1 R132 No IDH1 R132 
14 68 F Femur 18.0 G2 failed No IDH2 R172 
15 82 M Femur 7.5 Unknown Not tested No IDH1 R132C 
16 78 M Femur 15.0 G1 failed No IDH2 R172 
17 58 M Liver (met) Unknown Unknown Not tested No WT 
18 69 M Humerus 15.2 G1 failed No IDH2 R172 
19 57 M Pelvis 7.7 Unknown Not tested No IDH1 R132H 
20 72 M Pelvis 10.0 G2 IDH2 R172 No IDH2 R172 
21 62 M Femur 9.7 G2 failed No IDH2 R172 
22 67 F Pelvis 7.8 G2 failed No WT 
23 72 F Humerus 17.0 G1 IDH1 R132 No IDH1 R132 
Abbreviations: C-CHS, conventional component of chondrosarcoma; dediff CHS, dedifferentiated 
component of chondrosarcoma. 
met: metastatic; WT: wild type.  
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Table 3. Clinicopathologic Features and IDH1/2 Mutation Analysis of Table 3. Clinicopathologic Features and 
IDH1/2 Mutation Analysis of Undifferentiated Pleomorphic Sarcomas of Bone 
Cases Age 
(y) 
Sex Site Size 
(cm) 
Grade Decal Mutation 
1 73 F Left tibia 6.2 High  No WT 
2 82 F Right femur 6.0 High  No WT 
3 82 M Right humerus 8.5 High  No WT 
4 63 M Left femur 10.0 High  No WT 
5 67 M Right femur 7.5 High  No WT 
6 86 F Left femur 7.5 High  No WT 
7 41 M Left femur 7.0 High  No WT 
8 68 F Right tibia 3.0 High  No WT 
9 45 F Left femur 11.0 High  No WT 
10 71 M Right leg 9.0 High  No WT 
11 25 F Left femur 11.0 High  No WT 
12 88 F Right femur 12.5 High  No WT 
13 24 F left fibula 8.5 High  No WT 
14 88 F Right femur 8.5 High  No WT 
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Highlights 
 Morphologically difficult to distinguish the dedifferentiated chondrosarcoma from UPS 
of bone  
 Identification of IDH1/2 mutations supports the diagnosis of dedifferentiated 
chondrosarcoma 
 IDH1/2 mutation analysis using Qiagen IDH1/2 RGQ PCR Kit can be performed in any 
laboratory 
